Metastatic carcinoma of the prostate with hypercalcemia

Avashia, J. H.; Walsh, T. D.; Thomas, Anil; Kaye, Mitchell C.; Licata, Angelo A.

doi:10.3949/ccjm.57.7.636

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…), direct-release mechanism (osteolytic stimulation via neoplastic cells), epidermal growth factors (EGF), transforming growth factors (TGF) and lastly inherent tumor mosaicism. [3,4] Laboratory results on our patient ruled out hyperparathyroidism and PTHrp related hypercalcemia. Our Imaging studies indicated a osteoblastic nature of lesions favoring a positive calcium balance, suggesting a different underlying pathophysiology of mineral metabolism in these patients [1,4].…”

Section: Discussionmentioning

confidence: 77%

“…Prostate cancer is typically associated with metastatic osteoblastic lesions, hypocalcemia and hypophosphatemia. [1,2,3] Hypercalcemia is rarely encountered in prostate cancer, although it is well associated with other malignant cancers involving breast, lung, head, neck and multiple myelomas. [1,2] Despite affinity of prostate cancer towards skeletal metastases, only 1-2% of patients present with hypercalcemia.…”

Section: Discussionmentioning

confidence: 99%

“…[1,2] Despite affinity of prostate cancer towards skeletal metastases, only 1-2% of patients present with hypercalcemia. [3,5,6] Hypercalcemia may indicate a tumor recurrence or a preterminal event, including increased risk of detrimental skeletal events and death. [1,3] Many different mechanisms of malignancy associated hypercalcemia have been proposed, such as humoral mechanisms (PTH or PTH like peptides, prostaglandins etc.…”

Section: Discussionmentioning

confidence: 99%

“…[3,5,6] Hypercalcemia may indicate a tumor recurrence or a preterminal event, including increased risk of detrimental skeletal events and death. [1,3] Many different mechanisms of malignancy associated hypercalcemia have been proposed, such as humoral mechanisms (PTH or PTH like peptides, prostaglandins etc. ), direct-release mechanism (osteolytic stimulation via neoplastic cells), epidermal growth factors (EGF), transforming growth factors (TGF) and lastly inherent tumor mosaicism.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Hypercalcemia in Advanced Prostatic Carcinoma: A Rare Event

Mathews¹,

Kumar²,

Awkar³

et al. 2015

AJMCR

View full text Add to dashboard Cite

Prostate cancer is typically associated with metastatic osteoblastic lesions, hypocalcemia and hypophosphatemia. Hypercalcemia is a rarely encountered phenomenon i.e. 1-2% in prostate cancer, although it is well associated with other malignant cancers involving breast, lung, head, neck and multiple myelomas. We present the case of a 63 year old Mexican man with history of advanced prostatic adenocarcinoma and trans-urethral resection of prostate presented to ER with nausea, vomiting, polydipsia and altered mental status. Clinically, he appeared dehydrated and pale, with no other remarkable findings. Laboratory findings indicated severe hypercalcemia with calcium-16.1 mg/dL, with imaging studies revealing extensive metastatic osteoblastic lesions. Our patient was treated with aggressive hydration, calcitonin and pamidronic acid, his clinical status improved with complete resolution of hypercalcemia. We have discussed the possible underlying mechanisms and their interplay involved in the presentation of hypercalcemia in prostate cancer, and that its occurence is unlikely due to skeletal metastases.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Hypercalcemia in Advanced Prostatic Carcinoma: A Rare Event

Mathews¹,

Kumar²,

Awkar³

et al. 2015

AJMCR

View full text Add to dashboard Cite

show abstract

“…Hypercalcemia in the setting of prostate cancer is a rare complication with an uncertain pathophysiology. 6 Several mechanisms have been proposed for hypercalcemia of malignancy, these comprise humoral hypercalcemia of malignancy mediated by increased PTHrP; local osteolytic hypercalcemia with secretion of other humoral factors; excess extrarenal activation of vitamin D (1,25[OH]2D); PTH secretion, ectopic or primary; and multiple concurrent etiologies. 7 PTHrP is the predominant mediator for hypercalcemia of malignancy and is estimated to account for 80% of hypercalcemia in patients with cancer.…”

Section: Discussionmentioning

confidence: 99%